Paclitaxel-bevacizumab in Advanced Lung Cancer

Inclusion Criteria: * 2nd or 3rd line of non squamous non small cell lung cancer of stage III or IV * Document progression at the time of the inclusion. At least, one previous chemotherapy line with platinum. Patient who had previous treatment with bevacizumab can be included. * Patient with active mutation of EGFR must have had on line of chemotherapy with platinum and one with Tyrosine kinase inhibitor of EGFR. * Patient with ALK rearrangement must have had at least one line of chemotherapy with platinum and one with crizotinib. Exclusion Criteria: * Mixed cancer small cells and non small cells or squamous lung cancer. * Central nervous system symptomatic metastasis or requiring immediate cerebral radiotherapy * patient who have had previous treatment with taxane (docetaxel, paclitaxel). Peri-operatory chemotherapy or chemoradiotherapy with taxane allowed if stopped more than 6 months before.